Comparative pharmacokinetic study of chewable and conventional carbamazepine in children

C. Cornaggia, S. Gianetti, D. Battino, T. Granata, A. Romeo, F. Viani, G. Limido, P. Genton, A. Portera-Sanchez, C. K. Benninger

Research output: Contribution to journalArticlepeer-review


Fifteen children (7 boys and 8 girls) with generalized tonic-clonic seizures (GTCS) and partial seizures with elementary or complex symptomatology, treated with carbamazepine (CBZ) alone (n = 7) or in combination with either phenobarbital (PB, n = 6) or clobazam (CLB, n = 2) given for at least 3 months at stable individualized doses and regimens, entered an open, within-patient, change-over study of consecutive periods, each lasting 2 weeks. During period 1, conventional CBZ was given; during period 2, a chewable CBZ formulation was substituted for conventional CBZ and given at the same total daily dosage with the same schedule as in period 1. Blood samples for measuring plasma concentration of both total CBZ and CBZ- 10,11 epoxide (CBZ-E) were taken on the last day of each period. No significant difference between the two periods was noted in the mean ± SD of C(max), Css mean, and area under the curve (AUC) of total CBZ and CBZ-E. The two different CBZ formulations, administered at the same total daily dosage, can be considered bioequivalent.

Original languageEnglish
Pages (from-to)158-160
Number of pages3
Issue number1
Publication statusPublished - 1993


  • Anticonvulsants
  • Carbamazepine
  • Children
  • Pharmacokinetics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Comparative pharmacokinetic study of chewable and conventional carbamazepine in children'. Together they form a unique fingerprint.

Cite this